TABLE 1.

Comparison of treatments for acute promyelocytic leukemia

Reference	Year	Induction therapy	Consolidation therapy and maintenance therapy	Outcome
NCCN guideline 3	2021	0.15 mg/Kg/d of Arsenic trioxide	Arsenic trioxide 0.15 mg/Kg 5/wk for 4 wk every 8 wk for total four cycles	–
		+45 mg/m2/d of ATRA until CR or until 60 times of arsenic trioxide administration	+ATRA 45 mg/m2/d for 2 wk every 4 wk for seven cycles
Mozafar Aznab 20	2017	0.15 mg/Kg/d of ATO until CR	0.15 mg/Kg/d of ATO for 28 d as a consolidation therapy	Mean DFS 101 mo and 97 mo (male and female)
			The same dose of ATO was given every 3‐4 mo for 14 d for 2 y as a maintenance therapy
Yamamoto et al 14	2009	ATRA 70 mg/body + 240 mg/m2 of behenoyle AraC for 5 d and 30 mg/m2 of Daunorubicin	0.15 mg/Kg/d of ATO
Vikram et al 11	2006	0.15 mg/Kg/d of ATO until CR	0.15 mg/Kg/d of ATO for 4 wk as a consolidation therapy	3‐y EFS 74.87% ± 5.6%
			0.15 mg/Kg/d of ATO for 10 d a month for 6 mo as a maintenance therapy	3‐y DFS
				87.21%±4.93%
				3‐year OS
				86.11% ± 4.08%

Abbreviations: ATO, arsenic trioxide; ATRA, all‐trans retinoic acid.